Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs

Nautilus Biotechnology, Inc.

2022-Q1 EPS reported -$0.13

Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.
Net loss $15.8M vs $8.4M in prior year; no revenue reported (pre-revenue proteomics platform).
Cash, cash equivalents, and investments $349.0M as of March 31, 2022.
Scientific progress: manuscript on single-molecule protein arrays, Genentech collaboration results, and AACR antibody data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.